Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Milestone Pharmaceuticals

12/08/2026 14:33

Milestone Pharmaceuticals Inc MIST.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -20 cents.  The mean expectation of six analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -22 cents to -17 cents per share.
Revenue was $559.00 thousand​; analysts expected $816.67 thousand. 
Milestone Pharmaceuticals Inc's reported EPS for the quarter was a loss of 21 cents​.
The company reported a quarterly loss of $28.61 million.
Milestone Pharmaceuticals Inc shares had fallen by 5.2% this quarter and lost 37.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $7.00, about 81.9% above its last closing price of $1.27
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.19
-0.21
Missed
Mar. 31 2026 
0.31
-0.20
Missed
Dec. 31 2025 
-0.16
-0.18
Missed
Sep. 30 2025 
-0.16
-0.12
Beat